New Study: Pharmacist Involvement Key to Reducing Cost of Biologics

Tuesday November 13, 2018

A recent Italian study published in Frontiers in Public Health examined the effect of including a pharmacist in the Department of Abdominal Oncology’s clinical multidisciplinary team at the National Cancer Institute of Naples, Italy. The study’s key finding was that “the reimbursement process of biologics in gastrointestinal oncology can be improved when a health policy reimbursement professional Pharmacist is integrated in the multidisciplinary team along with clinicians.”

The authors provide context:

“Uncertainty of clinical outcomes and high costs are among the main challenges of innovative drugs; the first issue needs to be faced with intensive clinical and translational research, the second one has prompted the adoption of refunding systems including MEA [Managed Entry Agreements]. The results of this report indicate that MEA are an important source of reimbursement for innovative drugs but this system requires highly skilled and dedicated personnel. In the new era of high-cost innovative biologic drugs, professionals figures, beside clinicians, should be involved in the management of economic-related issues of anti-neoplastic agents.”

Read the study to learn more about how pharmacists can help the reimbursement process.

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.


Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:



October 21–23, 2024 | Rockville, MD

GRx+Biosims™ 2024 is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Access the most recent information straight from experts at the Food and Drug Administration, grasp the latest policies shaping the industry, and acquire valuable insights to propel your professional development.